Jeannie Hou
About
Jeannie Hou is a scholar working on Molecular Biology, Oncology and Dermatology.
According to data from OpenAlex, Jeannie Hou has authored 31 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 14 papers in Oncology and 9 papers in Dermatology. Recurrent topics in Jeannie Hou's work include Hedgehog Signaling Pathway Studies (14 papers), Cancer and Skin Lesions (9 papers) and Nonmelanoma Skin Cancer Studies (8 papers). Jeannie Hou is often cited by papers focused on Hedgehog Signaling Pathway Studies (14 papers), Cancer and Skin Lesions (9 papers) and Nonmelanoma Skin Cancer Studies (8 papers). Jeannie Hou collaborates with scholars based in United States, Germany and France. Jeannie Hou's co-authors include Daniel I. H. Linzer, S. Nicholas Agoff, Barbara Wu, Aleksandar Sekulić, Axel Hauschild, Nicole Basset‐Séguin, Dirk Schadendorf, Michael R. Migden, Karl D. Lewis and Huibin Yue and has published in prestigious journals such as Science, Journal of Clinical Oncology and Blood.
In The Last Decade
Jeannie Hou
30 papers receiving 1.5k citations
Peers
Jeannie Hou
Ruby Phelps United States
D Marrano Italy
Nicolas Poulalhon France
Maarten P. Tabor Netherlands
Georgia M. Beasley United States
Amal Kanbour‐Shakir United States
Tanya Trippett United States
Paula Lopes Portugal
Ellen Moore United States
Nicole Massoll United States
Citations per year, relative to Jeannie Hou Jeannie Hou (= 1×)
peers
Ruby Phelps
Countries citing papers authored by Jeannie Hou
Since
Specialization
Citations
This map shows the geographic impact of Jeannie Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeannie Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeannie Hou more than expected).
Fields of papers citing papers by Jeannie Hou
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jeannie Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeannie Hou. The network helps show where Jeannie Hou may publish in the future.
Co-authorship network of co-authors of Jeannie Hou
This figure shows the co-authorship network connecting the top 25 collaborators of Jeannie Hou. A scholar is included among the top collaborators of Jeannie Hou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeannie Hou. Jeannie Hou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Cheah, Chan Y., Constantine S. Tam, Mary Ann Anderson, et al.. (2025). 145 | SONROTOCLAX (BGB‐11417), A NOVEL BCL2 INHIBITOR, PLUS ZANUBRUTINIB (ZANU) DEMONSTRATES DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY CLL/SLL: UPDATED PHASE 1 RESULTS. Hematological Oncology. 43(S3).
2.
Venetsanakos, Eleni, et al.. (2021). Abstract 1481: DAY101, a potent pan-RAF inhibitor with activity in preclinical models harboring MAPK pathway alterations beyond BRAF V600E mutation. Cancer Research. 81(13_Supplement). 1481–1481.
3.
Desai, Jayesh, B. Markman, Michael Friedländer, et al.. (2019). Abstract CT084: Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study. Clinical Trials. CT084–CT084.
4.
Desai, Jayesh, B. Markman, Michael Friedländer, et al.. (2019). Abstract CT084: Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study. Cancer Research. 79(13_Supplement). CT084–CT084.
5.
Qin, Shukui, Richard S. Finn, Masatoshi Kudo, et al.. (2019). RATIONALE 301 Study: Tislelizumab Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma. Future Oncology. 15(16). 1811–1822.
6.
Desai, Jayesh, Mark Voskoboynik, Ben Markman, et al.. (2018). Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors.. Journal of Clinical Oncology. 36(15_suppl). TPS3113–TPS3113.
7.
Horvath, Lisa G., Jayesh Desai, Shahneen Sandhu, et al.. (2017). Preliminary results from a subset of patients (pts) with advanced head and neck squamous carcinoma (HNSCC) in a dose-escalation and dose-expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb). Annals of Oncology. 28. v129–v130.
8.
Sekulić, Aleksandar, Michael R. Migden, Nicole Basset‐Séguin, et al.. (2017). Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 17(1). 332–332.
9.
Bhutani, Tina, Michael Abrouk, Camelia S. Sima, et al.. (2017). Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. Journal of the American Academy of Dermatology. 77(4). 713–718.
10.
Basset‐Séguin, Nicole, Hayley J. Sharpe, Nicolas Poulalhon, et al.. (2016). Resistances to vismodegibs in a French case series of 207 patients with locally advanced basal cell carcinoma.. Journal of Clinical Oncology. 34(15_suppl). 9562–9562.
11.
Sekulić, Aleksandar, Michael R. Migden, Karl D. Lewis, et al.. (2015). Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. Journal of the American Academy of Dermatology. 72(6). 1021–1026.e8.
12.
Nguyen-Nielsen, Mary, Lisa Wang, Lars Pedersen, et al.. (2015). The incidence of metastatic basal cell carcinoma (mBCC) in Denmark, 1997-2010. European Journal of Dermatology. 25(5). 463–468.
13.
Sofen, Howard, Kenneth G. Gross, Leonard H. Goldberg, et al.. (2015). A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. Journal of the American Academy of Dermatology. 73(1). 99–105.e1.
14.
McCusker, Margaret, Nicole Basset‐Séguin, Reinhard Dummer, et al.. (2014). Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease. European Journal of Cancer. 50(4). 774–783.
15.
Sekulić, Aleksandar, John D. Hainsworth, Karl D. Lewis, et al.. (2014). Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression.. Journal of Clinical Oncology. 32(15_suppl). 9081–9081.
16.
Chapman, Paul B., Axel Hauschild, Caroline Robert, et al.. (2011). Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas.. Journal of Clinical Oncology. 29(15_suppl). LBA4–LBA4.
17.
Chapman, Paul B., Axel Hauschild, Caroline Robert, et al.. (2011). Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma.
18.
Snyder, James T., et al.. (2007). Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production. Blood. 109(12). 5399–5406.
19.
Fowler, Daniel H., Jeannie Hou, Jonathan E. Foley, et al.. (2002). Phase I clinical trial of donor T-helper Type-2 cells after immunoablative, reduced intensity allogeneic PBSC transplant. Cytotherapy. 4(5). 429–430.
20.
Charlson, Mary E., James P. Hollenberg, Jeannie Hou, et al.. (2000). Realizing the potential of clinical judgment: a real-time strategy for predicting outcomes and cost for medical inpatients. The American Journal of Medicine. 109(3). 189–195.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ruby Phelps Breakdown of academic impact, for papers by D Marrano Breakdown of academic impact, for papers by Nicolas Poulalhon Breakdown of academic impact, for papers by Maarten P. Tabor Breakdown of academic impact, for papers by Georgia M. Beasley Breakdown of academic impact, for papers by Amal Kanbour‐Shakir Breakdown of academic impact, for papers by Tanya Trippett Breakdown of academic impact, for papers by Paula Lopes Breakdown of academic impact, for papers by Ellen Moore Breakdown of academic impact, for papers by Nicole Massoll